Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTIER: MB-CART2019.1 as Frontline Consolidation for High-Risk MCL
NCT07569965Phase 2Not yet recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
A Phase 2 trial of zamtocabtagene autoleucel in mantle cell lymphoma (MCL), sponsored by Miltenyi Biomedicine GmbH. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07569965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569965.